CPhG (Solvent) Instructions for Use
ATC Code
V07AC (Auxiliary agents for blood transfusion)
Clinical-Pharmacological Group
Donor blood preservative preparation
Pharmacotherapeutic Group
Hemopreservative-auxiliary substance
Pharmacological Action
Hemopreservative. It provides an anticoagulant effect by binding calcium cations with citrate anions.
Furthermore, dextrose serves as nutrition for blood cells, and phosphate supports the blood buffer system.
Indications
- Preservation of donor blood.
ICD codes
| ICD-10 code | Indication |
| Z51.4 | Preparatory procedures for subsequent treatment or examination, not elsewhere classified |
| ICD-11 code | Indication |
| QB9A | Preparatory procedures for subsequent treatment |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Collect blood strictly in accordance with the official “Instructions for the Collection of Preserved Donor Blood”.
Use a single container for the collection of one donor blood unit. The resulting preserved blood has a maximum shelf life of 21 days.
Before initiating the procedure, perform a visual inspection of the container to verify the integrity of the consumer packaging and the absence of leaks.
Adverse Reactions
Monitor for signs of allergic reactions in the recipient following transfusion of blood preserved with this solution.
Such reactions are infrequent but may include urticaria, pruritus, or more severe hypersensitivity responses.
Drug Interactions
Consider potential interactions with medications administered to the blood donor prior to collection or added to the blood unit during processing.
The citrate anticoagulant may potentiate the effects of other calcium-binding agents. Exercise caution when transfusing large volumes of citrate-preserved blood to patients receiving medications that affect calcium homeostasis.
Contraindications
- Hypersensitivity to any component of the solution, including citrate, dextrose, or phosphate compounds.
Overdose
Overdose is not applicable from direct use of the preservative solution. The primary risk arises from massive transfusion of blood preserved with citrate.
Monitor for citrate toxicity manifested as hypocalcemia (e.g., paresthesia, muscle twitching, ECG changes) and manage with intravenous calcium supplementation as required.
Special Precautions
Intended for blood transfusion departments and stations only.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Solution for hemopreservative 63 ml: bags
Marketing Authorization Holder
Rezerv-M, LLC (Russia)
Dosage Form
| CPhG | Solution for hemopreservative 63 ml: bags |
Dosage Form, Packaging, and Composition
Hemopreservative solution transparent, slightly yellowish or colorless.
| 1 L | |
| Sodium citrate pentasesquihydrate | 31.94 g |
| Dextrose monohydrate | 25.5 g |
| Sodium phosphate monobasic dihydrate | 2.51 g |
| Citric acid monohydrate | 3.27 g |
Excipients : water for injections up to 1 L.
63 ml – polymer containers for blood and its components with a volume of 500 ml (1) – polypropylene bags.
Solution for hemopreservative 43 ml or 63 ml: bags
Marketing Authorization Holder
Sintez PJSC (Russia)
Dosage Form
| CPhG | Solution for hemopreservative 43 ml or 63 ml: bags |
Dosage Form, Packaging, and Composition
Hemopreservative solution transparent, slightly yellowish or colorless.
| 1 L | |
| Sodium citrate pentasesquihydrate | 31.94 g |
| Dextrose monohydrate | 25.5 g |
| Sodium phosphate monobasic dihydrate | 2.51 g |
| Citric acid monohydrate | 3.27 g |
Excipients : water for injections up to 1 L.
63 ml – polymer containers for blood and its components with a volume of 500 ml (1) – polypropylene bags.
43 ml – polymer containers for blood and its components with a volume of 375 ml (1) – polypropylene bags.
Solution for hemopreservative: 63 ml container
Marketing Authorization Holder
Medpolymer Firm, JSC (Russia)
Dosage Form
| CPhG | Solution for hemopreservative: 63 ml container |
Dosage Form, Packaging, and Composition
Hemopreservative solution transparent, slightly yellowish or colorless.
| 1 L | |
| Sodium citrate pentasesquihydrate | 31.94 g |
| Dextrose monohydrate | 25.5 g |
| Sodium phosphate monobasic dihydrate | 2.51 g |
| Citric acid monohydrate | 3.27 g |
Excipients : water for injections up to 1 L.
63 ml – polymer containers for blood and its components with a volume of 500 ml (1) – polypropylene bags.
Mildronate capsules 500mg, 90pcs
OKI, sachets 80mg 2g, 12pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Cortexin, 10mg, 5ml, 10pcs
Phenibut-Vertex pills 250mg, 20pcs
Picamilon pills 50mg, 60pcs
Belosalic, ointment, 30g
Kagocel pills 12mg, 30pcs
Actovegin pills 200mg, 50pcs
Fenotropil pills 100mg, 60pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs
No-spa pills 40mg, 64pcs
Belosalic, lotion solution for external use spray 100ml
Arbidol, capsules 100mg, 40pcs
Ingavirin capsules 90mg, 10pcs
Nootropil pills 800mg, 30pcs 